Akers Biosciences, Inc. Provides Notice of Proposed Settlement of Derivative Litigation

Thorofare, New Jersey, Jan. 17, 2020 (GLOBE NEWSWIRE) — Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it reached a settlement agreement to settle two shareholder derivative actions: Watts v. Gormally, et al., No. 2:18-15992 (D.N.J.) and Chan v. Gormally, et al., No. 2:19-cv-4989 (D.N.J.). As previously reported, on October 2, 2019, the plaintiffs filed a motion for preliminary approval of the settlement. On January 8, 2020, the court entered an order that, among other things, granted preliminary approval of the settlement, approved the form and content of the parties’ proposed notice of the settlement, directed the Company to issue a press release containing the information in that notice by today, and scheduled a hearing on May 28, 2020 to consider final approval of the settlement. Accordingly, below are the contents of the court-approved notice of the proposed settlement.

About Akers Biosciences Inc.

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring health related information directly to the patient or clinician in a timely and cost-efficient manner.

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include the need for additional financing, and any risks detailed from time to time in Akers’ reports filed with the Securities and Exchange Commission, Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. The Company does not have any obligation to update these forward-looking statements other than as required by law.

Additional information on the company and its products can be found at www.akersbio.com.

Contact:
Investor Relations:   Hayden IR
                                 Brett Mass, Managing Partner
                                 Phone: (646) 536-7331
                                 Email: brett@haydenir.com
                                 www.haydenir.com

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

CALE WATTS, derivatively on behalf of
AKERS BIOSCIENCES, INC.,
  Case No.: 2:18-cv-15992
     
Plaintiff,   EXHIBIT B
     
vs.    
    NOTICE OF SETTLEMENT
JOHN J. GORMALLY, GARY M. RAUCH,
RAYMOND F. AKERS, JR., BILL J.
WHITE, RICHARD C. TARBOX III, and
CHRISTOPHER C. SHREIBER,
  TO CURRENT AKERS
STOCKHOLDERS
     
Defendants,    
     
and    
     
AKERS BIOSCIENCES, INC.,    
     
Nominal Defendant.    

NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTION

TO: ALL OWNERS OF AKERS BIOSCIENCES, INC. (“AKERS” OR THE “COMPANY”) COMMON STOCK (TICKER SYMBOL: AKER) AS OF OCTOBER 1, 2019, WHO CONTINUE TO OWN SUCH SHARES (“CURRENT AKERS STOCKHOLDERS”).

PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. THIS NOTICE RELATES TO A PROPOSED SETTLEMENT AND DISMISSAL OF STOCKHOLDER DERIVATIVE LITIGATION AND CONTAINS IMPORTANT INFORMATION REGARDING YOUR RIGHTS.

IF THE COURT APPROVES THE SETTLEMENT AND DISMISSAL OF THE DERIVATIVE ACTIONS, STOCKHOLDERS OF AKERS WILL BE FOREVER BARRED FROM CONTESTING THE APPROVAL OF THE PROPOSED SETTLEMENT AND FROM PURSUING RELEASED CLAIMS.

THIS ACTION IS NOT A “CLASS ACTION.” THUS, THERE IS NO COMMON FUND UPON WHICH YOU CAN MAKE A CLAIM FOR A MONETARY PAYMENT.

PLEASE TAKE NOTICE that this action is being settled on the terms in an Amended Stipulation and Agreement of Settlement, dated October 1, 2019 (the “Stipulation”). The purpose of this Notice is to inform you of:

  the existence of the above-captioned derivative action (“Derivative Action”) and a substantially similar related derivative action captioned, Chan, et al. v. Gormally, et al., Case No. 2:19-cv-4989 (D.N.J.) (the “Chan Action”) (together, the “Derivative Actions”),
  the proposed settlement between the Plaintiffs1 and the Defendants reached in the Derivative Actions (the “Settlement”),
   the hearing to be held by the Court to consider the fairness, reasonableness, and adequacy of the Settlement,
  Plaintiffs’ Counsel’s application for fees and expenses, and
  Plaintiffs’ Service Awards.

This Notice describes what steps you may take in relation to the Settlement. This Notice is not an expression of any opinion by the Court about the truth or merits of Plaintiffs’ claims or the Defendants’ defenses. This Notice is solely to advise you of the proposed Settlement of the Derivative Actions and of your rights in connection with the proposed Settlement.

Summary

On October 1, 2019, Plaintiffs Cale Watts, Tiffany Chan, Jasmine Henderson, and Don Danesh Wijesekera (“Plaintiffs”), Akers, in its capacity as a nominal defendant, and defendants John J. Gormally, Gary M. Rauch, Bill J. White, Richard C. Tarbox III, Christopher C. Schreiber, Robert E. Andrews, Raza Bokhari, and Joshua Silverman, Raymond F. Akers, Jr., Thomas Knox, and Brandon Knox, current and/or former officers or members of Akers’ Board of Directors, entered into the Stipulation in the above-captioned action filed derivatively on behalf of Akers, in the United States District Court for the District of New Jersey (the “Court”) against the Individual Defendants.2 The Settlement, as documented in the Stipulation, subject to the approval of the Court, is intended by the Settling Parties to fully, finally, and forever compromise, resolve, discharge, and settle the Released Claims and to result in the dismissal of the Derivative Actions with prejudice, upon the terms and subject to the conditions set forth in the Stipulation. The proposed Settlement requires the Company to adopt certain corporate governance measures and procedures, as outlined in Exhibit A to the Stipulation, and provides that the Akers Defendants shall cause their insurer to pay a Fee and Expense Award to Plaintiffs’ Counsel of three hundred twenty-five thousand dollars ($325,000.00) and Service Awards to Plaintiffs of one thousand five hundred dollars ($1,500.00) each to be paid from the Fee and Expense Award.

This notice is a summary only and does not describe all of the details of the Stipulation. For full details of the matters discussed in this summary, please see the full Stipulation posted on the Company’s website, http://www.akersbio.com/, contact counsel for Plaintiff Watts (“Plaintiff’s Counsel”) at the address listed below, or inspect the full Stipulation filed with the Clerk of the Court.

1All capitalized terms used in this notice, unless otherwise defined herein, are defined as set forth in the Stipulation.

2 Robert E. Andrews, Raza Bokhari, Joshua Silverman, Thomas Knox, and Brandon Knox are named as defendants only in the Chan Action.

What is the Lawsuit About?

The Derivative Actions are brought derivatively on behalf of Akers and allege that the Individual Defendants breached their fiduciary duties by making and/or causing Akers to make false and misleading statements of material fact to the investing public and failing to maintain internal controls at Akers.

Why is there a Settlement?

The Court has not decided in favor of the Defendants or the Plaintiffs. Instead, both sides agreed to the Settlement to avoid the distraction, costs, and risks of further litigation, and because the Settlement, including the corporate governance reforms that the Company will adopt as part of the Settlement, provides a substantial benefit to, and is in the best interests of, Akers and its stockholders.

The Defendants deny each and every allegation of wrongdoing or liability arising out of or relating in any way to the events, conduct, statements, acts, or omissions alleged in the Derivative Actions. The Defendants further assert that, at all times, they acted in good faith, and in a manner they reasonably believed to be and that was in the best interests of Akers and Akers’ stockholders. The Defendants assert that they have meritorious defenses to the claims in the Derivative Actions. Nonetheless, the Defendants have entered into the Stipulation, without admitting or conceding any fault, liability, wrongdoing, or damage whatsoever, in order to avoid the risks inherent in any lawsuit and the burden and expense of further litigation.

The Settlement Hearing and Your Right to Object to the Settlement

On January 8, 2020, the Court entered an order preliminarily approving the Stipulation and the Settlement contemplated therein (the “Preliminary Approval Order”) and providing for the notice of the Settlement to be made to Current Akers stockholders. The Preliminary Approval Order further provides that the Court will hold a hearing (the “Settlement Hearing”) on May 28, 2020 at 11:30 am. before the Honorable Esther Salas, U.S. District Court, District of New Jersey, Courtroom MLK 5A, located at the Martin Luther King Building and United States Courthouse, 50 Walnut Street, Newark, New Jersey 07101, to among other things: (i) determine whether the proposed Settlement is fair, reasonable and adequate and in the best interests of the Company and its stockholders; (ii) consider any objections to the Settlement submitted in accordance with this Notice; (iii) determine whether a judgment should be entered dismissing all claims in the Derivative Action with prejudice, and releasing the Released Claims against the Released Persons; (iv) consider the agreed-to Fee and Expense Award to Plaintiffs’ Counsel of attorneys’ fees and the reimbursement of expenses; (v) consider the Service Awards to Plaintiffs, which shall be funded from the Fee and Expense Award; and (vi) consider any other matters that may properly be brought before the Court in connection with the Settlement.

Any Current Akers Stockholder who wishes to object to the fairness, reasonableness, or adequacy of the Settlement as set forth in the Stipulation, or to the proposed award of attorneys’ fees and expenses, may file a with the Court a written objection. An objector must at least fourteen (14) calendar days prior to the Settlement Hearing: (1) file with the Clerk of the Court and serve upon the below listed counsel a written objection to the Settlement setting forth (a) the nature of the objection; (b) proof of ownership of Akers common stock as of October 1, 2019 and through the date of the Settlement Hearing, including the number of shares of Akers common stock held and the date of purchase; (c) any and all documentation or evidence in support of such objection; and (d) the identities of any cases, by name, court, and docket number, in which the stockholder or his, her, or its attorney has objected to a settlement in the last three years; and (2) if intending to appear and requesting to be heard at the Settlement Hearing, he, she, or it must, in addition to the requirements of (1) above, file with the Clerk of the Court and serve on the below counsel (a) a written notice of his, her, or its intention to appear at the Settlement Hearing; (b) a statement that indicates the basis for such appearance; (c) the identities of any witnesses he, she, or it intends to call at the Settlement Hearing and a statement as to the subjects of their testimony; and (d) any and all evidence that would be presented at the Settlement Hearing. Any objector who does not timely file and serve a notice of intention to appear in accordance with this paragraph shall be foreclosed from raising any objection to the Settlement and shall not be permitted to appear at the Settlement Hearing, except for good cause shown.

IF YOU MAKE A WRITTEN OBJECTION, IT MUST BE ON FILE WITH THE CLERK OF THE COURT NO LATER THAN May 14, 2020. The Clerk’s address is:

Clerk of the Court
U.S. DISTRICT COURT, DISTRICT OF NEW JERSEY
Courtroom MLK 5A
50 Walnut Street
Newark, NJ 07101

YOU ALSO MUST DELIVER COPIES OF THE MATERIALS TO PLAINTIFF’S COUNSEL AND AKERS DEFENDANTS’ COUNSEL SO THEY ARE RECEIVED NO LATER THAN May 14, 2020. Counsel’s addresses are:

Counsel for Plaintiff:
Timothy Brown
THE BROWN LAW FIRM, P.C.
240 Townsend Square
Oyster Bay, NY 11771

Counsel for the Akers Defendants:
Caryn Schechtman
DLA Piper LLP (US)
1251 Avenue of the Americas
27th Floor
New York, NY 10020

An objector may file an objection on his, her or its own or through an attorney hired at his, her or its own expense. If an objector hires an attorney to represent him, her or it for the purposes of making such objection, the attorney must serve a notice of appearance on the counsel listed above and file such notice with the Court no later than fourteen (14) calendar days before the Settlement Hearing. Any Akers stockholder who does not timely file and serve a written objection complying with the above terms shall be deemed to have waived, and shall be foreclosed from raising, any objection to the Settlement, and any untimely objection shall be barred. 

Any objector who files and serves a timely, written objection in accordance with the instructions above, may appear at the Settlement Hearing either in person or through counsel retained at the objector’s expense. Objectors need not attend the Settlement Hearing, however, in order to have their objections considered by the Court.

If you are a Current Akers Stockholder and do not take steps to appear in this action and object to the proposed Settlement, you will be bound by the Judgment of the Court and will forever be barred from raising an objection to such settlement in this or any other action or proceeding, and from pursuing any of the Released Claims.

If you held Akers common stock as of October 1, 2019 and continue to hold such stock, you may have certain rights in connection with the proposed Settlement. You may obtain further information by contacting counsel for Plaintiff at: Timothy Brown, The Brown Law Firm, P.C., 240 Townsend Square, Oyster Bay, NY 11771, Telephone: (516) 922-5427, Email: tbrown@thebrownlawfirm.net. Please Do Not Call the Court or Defendants with Questions About the Settlement.

T2 Biosystems Reports Granting of Inducement Award

LEXINGTON, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that it issued an inducement award to John Sperzel, the Company’s recently appointed Chief Executive Officer and President, in accordance with the terms of Mr. Sperzel’s employment agreement.

The award was made on January 8, 2020 under T2 Biosystems’ Inducement Award Plan (the “Inducement Plan”), which was adopted March 1, 2018 and amended and restated on January 8, 2020 and provides for the granting of equity awards to new employees of T2 Biosystems. The inducement award consists of an option to purchase 3,000,000 shares of T2 Biosystems common stock and has a ten-year term. The exercise price of the option was $1.15, which was the per-share closing price of T2 Biosystems common stock on the Nasdaq Capital Market on January 8, 2020. The option vests in equal monthly installments over the four-year period following the grant date. The award was approved by the independent compensation committee of T2 Biosystems’ board of directors and was granted as an inducement material to the new employee entering into employment with T2 Biosystems in accordance with Nasdaq Marketplace Rule 5635(c)(4).   

About T2 Biosystems:
T2 Biosystems, a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, T2Bacteria® Panel, and the T2Resistance Panel™ and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including products for the detection of additional species and antibiotic resistance markers of sepsis pathogens, and tests for Lyme disease.  

Media Contact:
Gina Kent, Vault Communications
gkent@vaultcommunications.com
610-455-2763

Investor Contact:
Zack Kubow, W2O Group
zkubow@w2ogroup.com
415-658-6436

CytomX Therapeutics Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2020 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced that on January 15, 2020, the Company granted three new employees options to purchase a total of 44,600 shares of the Company’s common stock at an exercise price per share equal to $7.82, which was the closing trading price on January 15, 2020, the date of the grant. 

The stock options were granted pursuant to the Company’s 2019 Employment Inducement Incentive Plan, which was approved by the Company’s board of directors in January 2020 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

About CytomX Therapeutics

CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while minimizing activity in healthy tissues. CytomX and its partners have four programs in the clinic.  The Company’s clinical stage pipeline includes cancer immunotherapies against clinically validated targets, including a PD-L1-targeting Probody therapeutic wholly owned by CytomX (CX-072) and a CTLA-4-targeting Probody therapeutic partnered with Bristol Myers Squibb (BMS-986249). The CytomX clinical stage pipeline also includes first-in-class Probody drug conjugates against highly attractive targets, including a CD166-targeting Probody drug conjugate wholly owned by CytomX (CX-2009), and a CD71-targeting Probody drug conjugate partnered with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that are considered to be inaccessible to conventional antibody drug conjugates due to their presence on many healthy tissues. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company and ImmunoGen, Inc. For more information, visit www.cytomx.com.

PROBODY is a registered trademark of CytomX Therapeutics.

Contact:

Investors and Media:

Christopher Keenan
VP, Investor Relations and Corporate Communications
ckeenan@cytomx.com
650-383-0823

Anchiano Therapeutics Announces Record Date for 2020 Annual General Meeting of Shareholders

CAMBRIDGE, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) — Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) announced today that its board of directors approved the record date for the Company’s 2020 Annual General Meeting of Shareholders (the “Annual Meeting”) to be held on or about March 23, 2020.  The matters raised by Access Industries Holdings LLC and Clal Biotechnology Industries Ltd. will be addressed at the Annual Meeting.  Holders of the Company’s ordinary shares and holders of the Company’s American Depositary Shares at the close of business on February 17, 2020, the record date, will be entitled to receive notice of, and to vote at, the Annual Meeting.

About the Company
The Company is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer in areas of significant clinical need, with offices in Cambridge, MA and Jerusalem, Israel.  The Company is developing small-molecule pan-RAS inhibitors and inhibitors of PDE10 and the b-catenin pathway.  For more information on the Company, please visit www.anchiano.com.

Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to risks and uncertainties.  These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions, many of which are beyond the control of the Company, including, without limitation, the risk factors and other matters set forth in its filings with the Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2018.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Company Contact:
Frank Haluska, M.D., Ph.D.
President and Chief Executive Officer
info@anchiano.com

Investor Contact:
Ashley R. Robinson
Managing Director
LifeSci Advisors, LLC
617-535-7742
arr@lifesciadvisors.com

Nova Leap Health Corp. Closes Second and Final Tranche of Oversubscribed Non-Brokered Private Placement

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN

HALIFAX, Nova Scotia, Jan. 17, 2020 (GLOBE NEWSWIRE) — NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or the “Company”), a 2019 TSX Venture 50™ ranked company focused on the home health care industry, closed the second and final tranche of its non-brokered private placement, previously announced on December 5, 2019, December 20, 2019 and January 14, 2020 (the “Offering”), through the issuance of unsecured subordinated convertible debentures (the “Debentures”) for gross proceeds of $756,000 on January 16, 2020. The aggregate gross proceeds raised in the first and second tranche of the Offering were $3,094,000.

The Debentures will mature five (5) years after the issue date (the “Maturity Date”) and will accrue interest at the rate of 8.0% per annum, payable semi-annually. At the holders’ option, the Debentures may be converted into common shares of Nova Leap at any time and from time to time, up to the Maturity Date, at a conversion price of CAD$0.52 per common share (the “Conversion Price”). At any time after the date that is one year following the issue date of the Debentures, the Company may force the conversion of the principal amount of the then outstanding Debentures at the Conversion Price on not less than 30 days’ notice if the daily volume weighted average trading price of the common shares is greater than CAD$0.78 for any 20 consecutive trading days.

An insider of the Company subscribed for an aggregate of $150,000 principal amount of Debentures in the final tranche.  The Company’s material change report in relation to the insider’s participation in the Offering will not have been filed at least 21 days before the closing of the Offering as the insider’s participation was not known at that time.   The Company paid a cash commission of $32,460 which was equal to 6.0% of the gross proceeds of the second tranche of the Offering raised through certain brokers.  The Debentures and any common shares issued thereunder are subject to a statutory hold period lasting four months and one day following the issue date of the Debentures. 

The proceeds from the Offering will be used for acquisition, expansion, working capital and general corporate purposes.

The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Nova Leap

Nova Leap is an acquisitive home health care services company operating in one of the fastest growing industries in the U.S. & Canada.  The Company performs a vital role within the continuum of care with an individual and family centered focus, particularly those requiring dementia care.  Nova Leap achieved the #10 Ranking in the 2019 TSX Venture 50™ in the Clean Technology & Life Sciences sector.  The Company is geographically diversified with operations in 5 different U.S. states: Vermont, New Hampshire, Massachusetts, Rhode Island and Oklahoma as well as Nova Scotia, Canada.

FORWARD LOOKING INFORMATION:

Certain information in this press release may contain forward-looking statements, such as statements regarding the use of the proceeds of the Offering. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. Risks that could cause results to differ from those stated in the forward-looking statements in this release include regulatory changes affecting the home care industry, unexpected increases in operating costs and competition from other service providers. All forward-looking statements, including any financial outlook or future-oriented financial information, contained in this press release are made as of the date of this release and included for the purpose of providing information about management’s current expectations and plans relating to the future. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in the Company’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.

CAUTIONARY STATEMENT:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: For further information:

Christopher Dobbin, CPA, CA, Director, President and CEO Nova Leap Health Corp., 
T: 902 401 9480   F:  902 482 5177 cdobbin@novaleaphealth.com

Generex Biotechnology Provides Investor Conference Call Details Tuesday January 21, 2020 at 9:30 AM

MIRAMAR, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced Call-in details for the upcoming investor conference call on Tuesday January 21, 2020 at 9:30 AM Eastern time.

The access information for the investor conference call is as follows:

Domestic US/Canada – 1-(866) 342-8588

Direct Toll / International – 1-(203) 518-9865,

Program Title: Generex Biotechnology Announces Investor Conference Call

Conference ID – 3654

Agenda:

  • Update on the 2:5 GNBT stock dividend and the 2:5 NuGenerex Immuno-Oncology (NGIO) stock dividend & the FINRA approval process
  • Share price review: Impact of irregular & illegal trading and plans to address wrongdoing
  • Go-forward plans to build and operate the Generex enterprise
  • Update on the progress toward the NuGenerex Immuno-Oncology (NGIO) spinout
  • Funding update
  • ALTuCELL closing update

As always, Generex President & Chief Executive Officer, Joseph Moscato welcomes questions from shareholders during the call.

About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato
646-599-6222

Todd Falls
1-800-391-6755 Extension 222
investor@generex.com

AVRA Medical Robotics Attends J.P. Morgan Healthcare Conference

ORLANDO, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) — AVRA Medical Robotics, Inc. (the “Company”) (OTCQB: AVMR), a medical software and artificial intelligence company that is in the process of building a fully autonomous medical robotic system through the use of new technologies combining artificial intelligence, machine learning and proprietary software; is attending the 38th J.P. Morgan Healthcare Conference in San Francisco this week. The Company is represented by its CEO, Barry Cohen.

Mr. Cohen has held meetings with various Investment Banking firms and potential strategic partners to update them on the Company’s progress with its medical software procedure program and the development status of its Autonomous Robotics Surgical System, as envisioned by the Company.

As Mr Cohen explains, “The potential of our robotic systems is to perform operations with greater precision than human hands are capable of.”

Contacts: Barry Cohen
  AVRA Medical Robotics, Inc.
  Chairman and CEO
  bcohen@avramedical.com

Note to Editors:

About AVRA Medical Robotics
AVRA Medical Robotics, Inc., (OTCQB: AVMR) is empowering doctors and the practice of surgery through the use of software and artificial intelligence. AVRA, with a research agreement in place with the University of Central Florida known for its advances in robotics and guidance systems, is developing a fully autonomous surgical robotic system that “robotizes” a wide range of surgical procedures currently being performed by human hands using surgical and non-surgical devices and instruments. AVRA is concentrating its research and development efforts to meet rising expectations of patients and practitioners alike for the precision, efficiencies and safety offered by robotics, artificial intelligence and proprietary software when combined with proven medical devices and surgical instruments. AVRA’s current focus is developing a treatment-independent precision guidance system, applicable to a variety of minimally and non-invasive procedures, to leverage the growing demand for practical medical robotic devices, with an initial focus on skin resurfacing aesthetic procedures.
For more information visit the company’s website at www.avramedical.com.

About the J.P. Morgan Healthcare Conference
The annual J.P. Morgan Healthcare Conference is known to be the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.           

Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or AVRA’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2019 Financial Results Conference Call

WOBURN, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2019 fourth quarter and full year financial results before the opening of the market on Thursday, January 23, 2020. The Company will host a conference call at 8:00 a.m., Eastern Time on January 23, 2020 to discuss its financial results as well as business developments affecting the Company.

The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 6728609. Internationally, the conference call may be accessed by dialing 661-378-9630 and using the same confirmation code. The earnings press release and accompanying condensed financial statements will be accessible from the Company’s website at www.NeuroMetrix.com under the “Investor Relations” tab.

A replay of the conference call will be available starting two hours after the call by dialing 855-859-2056, domestically and 404-537-3406, internationally. The confirmation code to access the replay is 6728609. The replay will be available for one week after the conference call.

About NeuroMetrix

NeuroMetrix is a leading developer of diagnostic and therapeutic neurostimulation-based medical devices. The company markets DPNCheck®, a rapid point-of-care diagnostic test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company also markets Quell®, a wearable neurostimulation device for chronic pain that is available over-the-counter. For more information, please visit NeuroMetrix.com.

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

Sanofi: information concerning the total number of voting rights and shares, December 2019

  

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi
a French société anonyme with a registered share capital of 2,504,039,842 €
Registered office : 54, rue La Boétie – 75008 Paris – France
Registered at the Paris Commercial and Companies Registry under number 395 030 844

Date  

Total number of
issued shares

 

Number of real
voting rights
(excluding treasury shares)
Theoretical number of
voting rights
(including treasury shares)*
December 31, 2019 1,253,846,111  

1,406,203,455

 

 

1,406,222,936

 

*  Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.

This information is also available on the internet website of sanofi under « Regulated Information in France »:https://www.sanofi.com/en/investors/sanofi-share-and-adrs/share-overview/shares-and-voting-rights/

Investor Relations Department
Europe Tel: + 33 1 53 77 45 45  US Tel: + 1 908 981 5560
e-mail: IR@sanofi.com

 

Media Relations Department
Tel: + 33 1 53 77 46 46
 e-mail: MR@sanofi.com

 

 

Attachment

MindPath Care Centers Wins WRAL’s Voters’ Choice Awards For Best Psychiatrist

DURHAM, N.C., Jan. 17, 2020 (GLOBE NEWSWIRE) — MindPath Care Centers, North Carolina’s largest outpatient mental and behavioral healthcare provider, has been voted by the Triangle Community as the “Best Psychiatrist” in WRAL’s Voters’ Choice Awards.  The award was announced during a special invite-only ceremony held on Thursday, January 9.  The Raleigh office of MindPath Care Centers was nominated and selected as a finalist in October 2019, and a second round of voting was completed in December.   

“We are honored that residents of the Triangle Community recognized MindPath Care Centers as a leading provider of mindcare services,” said Jeff Williams, CEO of MindPath Care Centers.  “This award validates our commitment to providing the best possible mental and behavioral health care.”

MindPath Care Center has offices in Asheville, Cary, Charlotte/Concord, Chapel Hill/Carrboro, Durham, Raleigh, Wake Forest and Wilson.

The “best of” ballot gives the WRAL-TV audience an opportunity to vote for their favorite people, businesses and services in Raleigh, Durham, Chapel Hill, Fayetteville and other areas of North Carolina.  For a complete list of winners, please visit: https://wral5.secondstreetapp.com/2019-WRAL-Voters-Choice-Awards/.    

About MindPath Care Centers
MindPath Care Centers at Carolina Partners in Mental HealthCare is committed to providing the highest quality and most comprehensive outpatient mindcare to help people navigate life’s challenges, whenever and wherever they need it.  Our unique, collaborative care approach and integration of the latest treatments and technologies ensure our patients receive the continuum of care required for optimal outcomes.  Our services are delivered at more than 20 locations and include medication management and individual therapy both in office and via telehealth, group therapy sessions and TMS (transcranial magnetic stimulation) therapy.  To help everyone seeking treatment, our 150+ providers participate in most major insurance plans.  For more information or to schedule an appointment, please visit www.mindpathcare.com.  You can also follow us on Facebook:  facebook.com/mindpathcare, Twitter:  twitter.com/mindpathcare, Instagram:  instagram.com/mindpathcare, and Snapchat.  

Media Contacts:
Nathan Abler, Dresner Corporate Services, (714) 742-4180, nabler@dresnerco.com
Joanne Tedesco, Dresner Corporate Services, (573) 355-7855, jtedesco@dresnerco.com